Gregory Vidal, MD, PhD, on Treating Patients with HER2+ Breast Cancer During COVID-19
The breast cancer expert discussed the changes he has made in treating this patient population as a result of the COVID-19 pandemic.
Due to the coronavirus disease 2019 (COVID-19) pandemic, oncologists have had to modify the ways they care and provide treatment for their patients with breast cancer, especially those with HER2-positive breast cancer.
Some of the changes implemented by oncologists have included telehealth visits as opposed to in-clinic visits, as well as delays in elective surgeries.
In an interview with CancerNetwork®, Gregory Vidal, MD, PhD, a medical oncologist at West Cancer Center and Research Institute and associate professor in the department of hematology/oncology at The University of Tennessee Health Science Center in Memphis, spoke about treating patients with HER2-positive breast cancer in the midst of the pandemic and the changes that his practice has implemented as a result.
This segment comes from the CancerNetwork® portion of the MJH Life Sciences Medical World News, airing daily on all MJH Life Sciences channels.
Treatment Combinations for HER2-Positive Breast Cancer
March 7th 2013As part of our coverage for the 30th Annual Miami Breast Cancer Conference, we bring you an interview with Dr. Mark Pegram, director of the breast cancer program at the Stanford Women’s Cancer Center and codirector of the molecular therapeutics program. Dr. Pegram will be discussing the potential for novel HER2 combination therapies at the conference.
